Global Immunotherapy Drugs for Neuroblastoma Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Immunotherapy Drugs for Neuroblastoma market size was valued at USD 46 million in 2022 and is forecast to a readjusted size of USD 63 million by 2029 with a CAGR of 4.4% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report is a detailed and comprehensive analysis for global Immunotherapy Drugs for Neuroblastoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Immunotherapy Drugs for Neuroblastoma
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Immunotherapy Drugs for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Immunotherapy Drugs for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Immunotherapy Drugs for Neuroblastoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Immunotherapy Drugs for Neuroblastoma, with price, sales, revenue and global market share of Immunotherapy Drugs for Neuroblastoma from 2018 to 2023.
Chapter 3, the Immunotherapy Drugs for Neuroblastoma competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Immunotherapy Drugs for Neuroblastoma breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Immunotherapy Drugs for Neuroblastoma market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Immunotherapy Drugs for Neuroblastoma.
Chapter 14 and 15, to describe Immunotherapy Drugs for Neuroblastoma sales channel, distributors, customers, research findings and conclusion.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report is a detailed and comprehensive analysis for global Immunotherapy Drugs for Neuroblastoma market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Immunotherapy Drugs for Neuroblastoma market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Immunotherapy Drugs for Neuroblastoma
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Immunotherapy Drugs for Neuroblastoma market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals and Baxter Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Immunotherapy Drugs for Neuroblastoma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Dinutuximab
- Naxitamab
- Other
- Hospital
- Clinic
- Other
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Immunotherapy Drugs for Neuroblastoma product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Immunotherapy Drugs for Neuroblastoma, with price, sales, revenue and global market share of Immunotherapy Drugs for Neuroblastoma from 2018 to 2023.
Chapter 3, the Immunotherapy Drugs for Neuroblastoma competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Immunotherapy Drugs for Neuroblastoma breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Immunotherapy Drugs for Neuroblastoma market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Immunotherapy Drugs for Neuroblastoma.
Chapter 14 and 15, to describe Immunotherapy Drugs for Neuroblastoma sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Dinutuximab
1.3.3 Naxitamab
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Immunotherapy Drugs for Neuroblastoma Market Size & Forecast
1.5.1 Global Immunotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
1.5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 United Therapeutics Recent Developments/Updates
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
2.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 EUSA Pharma Recent Developments/Updates
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ANI Pharmaceuticals Recent Developments/Updates
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
2.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Baxter Healthcare Recent Developments/Updates
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
2.7.4 Pfizer Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Recent Developments/Updates
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Teva Pharmaceuticals Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA BY MANUFACTURER
3.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
3.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.4.2 Top 6 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.5 Immunotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.5.1 Immunotherapy Drugs for Neuroblastoma Market: Region Footprint
3.5.2 Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.5.3 Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
4.1.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
4.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.3 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.4 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.5 South America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.6 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
5.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)
5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
6.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
7.2 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
7.3 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country
7.3.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
7.3.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
8.2 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
8.3 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.3.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
8.3.2 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region
9.3.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
10.2 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
10.3 South America Immunotherapy Drugs for Neuroblastoma Market Size by Country
10.3.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
10.3.2 South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Market Size by Country
11.3.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Immunotherapy Drugs for Neuroblastoma Market Drivers
12.2 Immunotherapy Drugs for Neuroblastoma Market Restraints
12.3 Immunotherapy Drugs for Neuroblastoma Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Immunotherapy Drugs for Neuroblastoma and Key Manufacturers
13.2 Manufacturing Costs Percentage of Immunotherapy Drugs for Neuroblastoma
13.3 Immunotherapy Drugs for Neuroblastoma Production Process
13.4 Immunotherapy Drugs for Neuroblastoma Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Immunotherapy Drugs for Neuroblastoma Typical Distributors
14.3 Immunotherapy Drugs for Neuroblastoma Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Immunotherapy Drugs for Neuroblastoma
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Dinutuximab
1.3.3 Naxitamab
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Other
1.5 Global Immunotherapy Drugs for Neuroblastoma Market Size & Forecast
1.5.1 Global Immunotherapy Drugs for Neuroblastoma Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029)
1.5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 United Therapeutics
2.1.1 United Therapeutics Details
2.1.2 United Therapeutics Major Business
2.1.3 United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.1.4 United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 United Therapeutics Recent Developments/Updates
2.2 Y-mAbs Therapeutics
2.2.1 Y-mAbs Therapeutics Details
2.2.2 Y-mAbs Therapeutics Major Business
2.2.3 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
2.2.4 Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
2.3 EUSA Pharma
2.3.1 EUSA Pharma Details
2.3.2 EUSA Pharma Major Business
2.3.3 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
2.3.4 EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 EUSA Pharma Recent Developments/Updates
2.4 ANI Pharmaceuticals
2.4.1 ANI Pharmaceuticals Details
2.4.2 ANI Pharmaceuticals Major Business
2.4.3 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.4.4 ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ANI Pharmaceuticals Recent Developments/Updates
2.5 Baxter Healthcare
2.5.1 Baxter Healthcare Details
2.5.2 Baxter Healthcare Major Business
2.5.3 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
2.5.4 Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Baxter Healthcare Recent Developments/Updates
2.6 Ingenus Pharmaceuticals
2.6.1 Ingenus Pharmaceuticals Details
2.6.2 Ingenus Pharmaceuticals Major Business
2.6.3 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.6.4 Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
2.7.4 Pfizer Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Recent Developments/Updates
2.8 Hikma Pharmaceuticals
2.8.1 Hikma Pharmaceuticals Details
2.8.2 Hikma Pharmaceuticals Major Business
2.8.3 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.8.4 Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
2.9 Teva Pharmaceuticals
2.9.1 Teva Pharmaceuticals Details
2.9.2 Teva Pharmaceuticals Major Business
2.9.3 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
2.9.4 Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Teva Pharmaceuticals Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: IMMUNOTHERAPY DRUGS FOR NEUROBLASTOMA BY MANUFACTURER
3.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023)
3.2 Global Immunotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023)
3.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.4.2 Top 6 Immunotherapy Drugs for Neuroblastoma Manufacturer Market Share in 2022
3.5 Immunotherapy Drugs for Neuroblastoma Market: Overall Company Footprint Analysis
3.5.1 Immunotherapy Drugs for Neuroblastoma Market: Region Footprint
3.5.2 Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
3.5.3 Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Immunotherapy Drugs for Neuroblastoma Market Size by Region
4.1.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
4.1.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
4.1.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2029)
4.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.3 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.4 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.5 South America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
4.6 Middle East and Africa Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
5.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2029)
5.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
6.2 Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2029)
6.3 Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
7.2 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
7.3 North America Immunotherapy Drugs for Neuroblastoma Market Size by Country
7.3.1 North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
7.3.2 North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
8.2 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
8.3 Europe Immunotherapy Drugs for Neuroblastoma Market Size by Country
8.3.1 Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
8.3.2 Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Market Size by Region
9.3.1 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
10.2 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
10.3 South America Immunotherapy Drugs for Neuroblastoma Market Size by Country
10.3.1 South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
10.3.2 South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Market Size by Country
11.3.1 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Immunotherapy Drugs for Neuroblastoma Market Drivers
12.2 Immunotherapy Drugs for Neuroblastoma Market Restraints
12.3 Immunotherapy Drugs for Neuroblastoma Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Immunotherapy Drugs for Neuroblastoma and Key Manufacturers
13.2 Manufacturing Costs Percentage of Immunotherapy Drugs for Neuroblastoma
13.3 Immunotherapy Drugs for Neuroblastoma Production Process
13.4 Immunotherapy Drugs for Neuroblastoma Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Immunotherapy Drugs for Neuroblastoma Typical Distributors
14.3 Immunotherapy Drugs for Neuroblastoma Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. United Therapeutics Major Business
Table 5. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 6. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. United Therapeutics Recent Developments/Updates
Table 8. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
Table 9. Y-mAbs Therapeutics Major Business
Table 10. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 11. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Y-mAbs Therapeutics Recent Developments/Updates
Table 13. EUSA Pharma Basic Information, Manufacturing Base and Competitors
Table 14. EUSA Pharma Major Business
Table 15. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
Table 16. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. EUSA Pharma Recent Developments/Updates
Table 18. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. ANI Pharmaceuticals Major Business
Table 20. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 21. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. ANI Pharmaceuticals Recent Developments/Updates
Table 23. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 24. Baxter Healthcare Major Business
Table 25. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
Table 26. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Baxter Healthcare Recent Developments/Updates
Table 28. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 29. Ingenus Pharmaceuticals Major Business
Table 30. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 31. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Ingenus Pharmaceuticals Recent Developments/Updates
Table 33. Pfizer Basic Information, Manufacturing Base and Competitors
Table 34. Pfizer Major Business
Table 35. Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
Table 36. Pfizer Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Pfizer Recent Developments/Updates
Table 38. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 39. Hikma Pharmaceuticals Major Business
Table 40. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 41. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Hikma Pharmaceuticals Recent Developments/Updates
Table 43. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Teva Pharmaceuticals Major Business
Table 45. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 46. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Teva Pharmaceuticals Recent Developments/Updates
Table 48. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 49. Global Immunotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023) & (USD Million)
Table 50. Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 51. Market Position of Manufacturers in Immunotherapy Drugs for Neuroblastoma, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 52. Head Office and Immunotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 53. Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 54. Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 55. Immunotherapy Drugs for Neuroblastoma New Market Entrants and Barriers to Market Entry
Table 56. Immunotherapy Drugs for Neuroblastoma Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 58. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 59. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 60. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 61. Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 62. Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 63. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 64. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 65. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 68. Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 69. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 71. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2023) & (USD Million)
Table 72. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2024-2029) & (USD Million)
Table 73. Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 74. Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 75. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 76. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 77. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 78. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 79. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 80. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 81. North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 82. North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 84. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 85. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 86. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 87. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 88. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 89. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 92. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 93. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 94. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 95. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 96. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 97. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 98. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 99. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 100. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 101. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 102. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 103. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 104. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 105. South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 106. South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 107. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 108. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 109. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 111. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 112. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 113. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 114. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 115. Immunotherapy Drugs for Neuroblastoma Raw Material
Table 116. Key Manufacturers of Immunotherapy Drugs for Neuroblastoma Raw Materials
Table 117. Immunotherapy Drugs for Neuroblastoma Typical Distributors
Table 118. Immunotherapy Drugs for Neuroblastoma Typical Customers
Table 1. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. United Therapeutics Basic Information, Manufacturing Base and Competitors
Table 4. United Therapeutics Major Business
Table 5. United Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 6. United Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. United Therapeutics Recent Developments/Updates
Table 8. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
Table 9. Y-mAbs Therapeutics Major Business
Table 10. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Product and Services
Table 11. Y-mAbs Therapeutics Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Y-mAbs Therapeutics Recent Developments/Updates
Table 13. EUSA Pharma Basic Information, Manufacturing Base and Competitors
Table 14. EUSA Pharma Major Business
Table 15. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Product and Services
Table 16. EUSA Pharma Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. EUSA Pharma Recent Developments/Updates
Table 18. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 19. ANI Pharmaceuticals Major Business
Table 20. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 21. ANI Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. ANI Pharmaceuticals Recent Developments/Updates
Table 23. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
Table 24. Baxter Healthcare Major Business
Table 25. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Product and Services
Table 26. Baxter Healthcare Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Baxter Healthcare Recent Developments/Updates
Table 28. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 29. Ingenus Pharmaceuticals Major Business
Table 30. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 31. Ingenus Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Ingenus Pharmaceuticals Recent Developments/Updates
Table 33. Pfizer Basic Information, Manufacturing Base and Competitors
Table 34. Pfizer Major Business
Table 35. Pfizer Immunotherapy Drugs for Neuroblastoma Product and Services
Table 36. Pfizer Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Pfizer Recent Developments/Updates
Table 38. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 39. Hikma Pharmaceuticals Major Business
Table 40. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 41. Hikma Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Hikma Pharmaceuticals Recent Developments/Updates
Table 43. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Teva Pharmaceuticals Major Business
Table 45. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Product and Services
Table 46. Teva Pharmaceuticals Immunotherapy Drugs for Neuroblastoma Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Teva Pharmaceuticals Recent Developments/Updates
Table 48. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 49. Global Immunotherapy Drugs for Neuroblastoma Revenue by Manufacturer (2018-2023) & (USD Million)
Table 50. Global Immunotherapy Drugs for Neuroblastoma Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 51. Market Position of Manufacturers in Immunotherapy Drugs for Neuroblastoma, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 52. Head Office and Immunotherapy Drugs for Neuroblastoma Production Site of Key Manufacturer
Table 53. Immunotherapy Drugs for Neuroblastoma Market: Company Product Type Footprint
Table 54. Immunotherapy Drugs for Neuroblastoma Market: Company Product Application Footprint
Table 55. Immunotherapy Drugs for Neuroblastoma New Market Entrants and Barriers to Market Entry
Table 56. Immunotherapy Drugs for Neuroblastoma Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 58. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 59. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 60. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 61. Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2018-2023) & (US$/Unit)
Table 62. Global Immunotherapy Drugs for Neuroblastoma Average Price by Region (2024-2029) & (US$/Unit)
Table 63. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 64. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 65. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2018-2023) & (USD Million)
Table 66. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type (2024-2029) & (USD Million)
Table 67. Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2023) & (US$/Unit)
Table 68. Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2024-2029) & (US$/Unit)
Table 69. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 71. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2018-2023) & (USD Million)
Table 72. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application (2024-2029) & (USD Million)
Table 73. Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2023) & (US$/Unit)
Table 74. Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2024-2029) & (US$/Unit)
Table 75. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 76. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 77. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 78. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 79. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 80. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 81. North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 82. North America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 83. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 84. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 85. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 86. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 87. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 88. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 89. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 90. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 91. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 92. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 93. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 94. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 95. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 96. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 97. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 98. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 99. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 100. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 101. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 102. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 103. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2018-2023) & (K Units)
Table 104. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity by Country (2024-2029) & (K Units)
Table 105. South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2018-2023) & (USD Million)
Table 106. South America Immunotherapy Drugs for Neuroblastoma Consumption Value by Country (2024-2029) & (USD Million)
Table 107. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2018-2023) & (K Units)
Table 108. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Type (2024-2029) & (K Units)
Table 109. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Application (2024-2029) & (K Units)
Table 111. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2018-2023) & (K Units)
Table 112. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity by Region (2024-2029) & (K Units)
Table 113. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 114. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value by Region (2024-2029) & (USD Million)
Table 115. Immunotherapy Drugs for Neuroblastoma Raw Material
Table 116. Key Manufacturers of Immunotherapy Drugs for Neuroblastoma Raw Materials
Table 117. Immunotherapy Drugs for Neuroblastoma Typical Distributors
Table 118. Immunotherapy Drugs for Neuroblastoma Typical Customers
LIST OF FIGURES
Figure 1. Immunotherapy Drugs for Neuroblastoma Picture
Figure 2. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type in 2022
Figure 4. Dinutuximab Examples
Figure 5. Naxitamab Examples
Figure 6. Other Examples
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application in 2022
Figure 9. Hospital Examples
Figure 10. Clinic Examples
Figure 11. Other Examples
Figure 12. Global Immunotherapy Drugs for Neuroblastoma Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Immunotherapy Drugs for Neuroblastoma Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Immunotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Immunotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 54. China Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Immunotherapy Drugs for Neuroblastoma Market Drivers
Figure 75. Immunotherapy Drugs for Neuroblastoma Market Restraints
Figure 76. Immunotherapy Drugs for Neuroblastoma Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Immunotherapy Drugs for Neuroblastoma in 2022
Figure 79. Manufacturing Process Analysis of Immunotherapy Drugs for Neuroblastoma
Figure 80. Immunotherapy Drugs for Neuroblastoma Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
Figure 1. Immunotherapy Drugs for Neuroblastoma Picture
Figure 2. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type in 2022
Figure 4. Dinutuximab Examples
Figure 5. Naxitamab Examples
Figure 6. Other Examples
Figure 7. Global Immunotherapy Drugs for Neuroblastoma Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application in 2022
Figure 9. Hospital Examples
Figure 10. Clinic Examples
Figure 11. Other Examples
Figure 12. Global Immunotherapy Drugs for Neuroblastoma Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Immunotherapy Drugs for Neuroblastoma Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Immunotherapy Drugs for Neuroblastoma Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Immunotherapy Drugs for Neuroblastoma by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Immunotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Immunotherapy Drugs for Neuroblastoma Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Immunotherapy Drugs for Neuroblastoma Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Immunotherapy Drugs for Neuroblastoma Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 54. China Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Immunotherapy Drugs for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Immunotherapy Drugs for Neuroblastoma Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Immunotherapy Drugs for Neuroblastoma Market Drivers
Figure 75. Immunotherapy Drugs for Neuroblastoma Market Restraints
Figure 76. Immunotherapy Drugs for Neuroblastoma Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Immunotherapy Drugs for Neuroblastoma in 2022
Figure 79. Manufacturing Process Analysis of Immunotherapy Drugs for Neuroblastoma
Figure 80. Immunotherapy Drugs for Neuroblastoma Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
